Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Atorvastatin shown to decrease heart disease and stroke

11.10.2002


Atorvastatin shown to decrease heart disease and stroke in patients with hypertension and low cholesterol



A major European trial studying different blood pressure treatments and the effects of additional cholesterol lowering, announces today that it has stopped part of its trial earlier than expected because results collected already show a significant benefit to patients on one of its treatments.

It found that among 10,297 patients with hypertension and cholesterol levels lower than currently recommended for treatment, those given the cholesterol-lowering drug atorvastatin suffered significantly less heart attacks and strokes compared to those receiving the placebo treatment.


The International Steering Committee of the independent Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) have stopped the relevant part of the trial and informed fellow investigators, their patients and the regulatory authorities about the newly emerged results.

The rest of the trial, which compares different blood pressure treatment strategies, will continue unchanged.

"The trial shows that patients with high blood pressure but low cholesterol benefit clearly from taking a statin. It is too early to quantify the precise size of the effect, but we expect to see a reduction in heart attacks of about one-third among those taking a statin," say ASCOT study co-chairmen Björn Dahlöf from the Sahlgrenska University Hospital, Östra, Sweden and Peter Sever from Imperial College London, UK.

"However the ASCOT trial still continues and we wish to make it clear to all our patients that this new information does not mean they should stop the tablets they are taking. It is vital that all patients on the trial carry on with their treatment regimens," they add.

All patients will be recalled to visit their ASCOT doctors and will be examined again in the coming weeks

Members of ASCOT’s Data Safety Monitoring Board, who work independently of the trial investigators and are the only researchers permitted to look at the results of the five-year old trial while it is ongoing, reported their findings to the ASCOT International Steering Committee on 2 September 2002.

They described a highly significant reduction in the number of heart attacks and a significant reduction in the number of strokes experienced by those patients receiving atorvastatin compared to placebo.

As the size of the benefit exceeded the stopping rules for this part of the trial, the Data Safety Monitoring Board’s recommendations to close this section of the study were accepted by the ASCOT Steering Committee. This part of the study was formally closed on 1 October 2002 but data collection relating to it is expected to continue until the end of December 2002.

Further announcements about the results of the atorvastatin part of the trial will be made in 2003, with final results of the whole ASCOT study expected in 2004.

Patients were only eligible for the cholesterol lowering part of the trial if they had a blood cholesterol level of 6.5 mmol per litre or less - a significantly lower range of cholesterol levels than is usually treated by doctors. This part of the trial is specifically aimed to discover if a statin would confer additional protection against coronary heart disease in hypertensive patients with low cholesterol levels.

The other primary objective of ASCOT is to compare a new treatment strategy for hypertension against an old one, and discover which is better at preventing heart attacks.

The new treatment is a calcium channel blocker (amlodipine), to which in the majority of patients the angiotensin converting enzyme inhibitor, perindopril, is added to achieve the goal blood pressure. The older treatment is a beta blocker (atenolol), to which in the majority of patients a diuretic, bendrofluazide, is added to achieve goal blood pressure.

By May 2000, 19,342 patients had been entered on the trial and randomly selected to receive one of the two blood pressure lowering strategies. Out of the trial total 10,297 patients with low cholesterol were also randomised to receive either placebo or atorvastatin.

Patients in the trial are aged between 40 and 79 years old, with high blood pressure and have at least three other pre-specified cardiovascular risk factors.

The primary endpoint of the trial is either a heart attack from which the patient survives or death from coronary heart disease. A large number of other cardiovascular events including stroke are identified as secondary endpoints in the study.


###

Tony Stephenson | EurekAlert!
Further information:
http://www.ascotstudy.com

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>